Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
| Autor: | Jia-Ying Wu, Yi Xiao, Yicheng Zhang, Jianfeng Zhou, Fankai Meng, Yang Cao, Na Wang, Xiaojian Zhu, Jue Wang, Lifang Huang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology medicine.medical_specialty Lymphoma medicine.medical_treatment Antigens CD19 Cancer immunotherapy Immunotherapy Adoptive Transplantation Autologous Article CD19 Central Nervous System Neoplasms Young Adult 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Refractory Internal medicine medicine Humans Multiple myeloma RC254-282 Receptors Chimeric Antigen biology business.industry Hematopoietic Stem Cell Transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hematology Immunotherapy Middle Aged Antigens CD20 medicine.disease Chimeric antigen receptor 030104 developmental biology 030220 oncology & carcinogenesis Toxicity biology.protein Female business |
| Zdroj: | Blood Cancer Journal, Vol 11, Iss 7, Pp 1-8 (2021) Blood Cancer Journal |
| ISSN: | 2044-5385 |
| Popis: | Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. Here, we treated 13 CNSL patients with ASCT sequential CD19/22 CAR T-cell infusion and simultaneously evaluated the clinical efficacy and toxicity. The 13 CNSL patients analyzed included four primary CNSL and nine secondary CNSL patients. Patients 1 and 10, who had complete remission status before enrollment, maintained clinical efficacy without recurrence. Nine of the remaining 11 patients responded to our protocol with a median durable time of 14.03 months, and the overall response and complete remission rate were 81.81% and 54.55%, respectively. No patient suffered grades 3–4 cytokine-release syndrome (CRS), and only patient 10 experienced severe immune effector cell-associated neurotoxicity syndrome (ICANS). In addition, increases in serum ferritin and interleukin-6 levels were often accompanied by CRS and ICANS. After a median follow-up time of 14.20 months, the estimated 1-year progression-free survival and overall survival rates were 74.59% and 82.50%, respectively. Sequential CD19/22 CAR T-cell immunotherapy following ASCT as a novel method for CNSL appears to have encouraging long-term efficacy with relatively manageable side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink